Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Bio-Path Holdings nets $17.2mm through registered direct offering

Executive Summary

Bio-Path Holdings Inc. (using its DNAbilize delivery platform to develop RNAi nanoparticle drugs for cancer) netted $17.2mm in a registered direct offering of 712,910 common shares at $25.95 (a 101% premium to the ten-day pre-announcement market average). A week prior to the RDO, Bio-Path announced positive interim data analysis of a Phase II trial with lead candidate prexigebersen in acute myeloid leukemia. This news caused the company's stock to jump from $4.62 per share to $38.86 in just two days. The day of the offering, trading closed at $35.13.
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Nanotechnology, Chips, etc.
  • Pharmaceuticals
    • Drug Delivery
Deal Status
  • Final
Deal Type
  • Financing
    • Private Investment in Public Equity
    • Private Placement

Related Companies